Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 3,107 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Treatment of depression Clear all

Conditions: Major Depressive Disorder
Interventions: ALKS 5461, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Colton, California • Garden Grove, California + 29 more

Conditions: Major Depressive Disorder
Interventions: CT-152 - Digital Therapeutic, Sham; Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 22 Years to 64 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cognitive-affective Exercises, Engaging Exercises
Interventions: Therapeutic Computerized intervention, Nontherapeutic computerized intervention; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Depressive Disorder
Interventions: Saredutant (SR48968C), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Treatment Resistant Depression
Interventions: Liafensine, Placebo; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 41
States / cities: Huntsville, Alabama • Phoenix, Arizona • Garden Grove, California + 36 more

Conditions: Multiple Sclerosis
Interventions: Brief telephone-based counseling, Education counseling; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Substance Withdrawal Syndrome
Interventions: Melatonin, Matched Placebo; Dietary Supplement
Lead sponsor: Duquesne University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depressive Episodes, Bipolar I Depression
Interventions: SEP-4199 CR; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more

Conditions: Treatment Resistant Depression (TRD)
Interventions: Transmagnetic Stimulation, Electroconvulsive Therapy; Device
Lead sponsor: Austin Messner; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Stress Disorders, Post-Traumatic
Interventions: Emotional Freedom Techniques (EFT); Behavioral
Lead sponsor: Soul Medicine Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Santa Rosa, California

Conditions: Major Depression
Interventions: behavior therapy, Medication prescribed by PCP; Behavioral · Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Pawtucket, Rhode Island • Providence, Rhode Island

Conditions: Cognitive Behavioral Therapy
Interventions: cognitive behavioral therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, Anxiety
Interventions: IDgenetix Neuropsychiatric Test Panel; Genetic
Lead sponsor: AltheaDx; Industry
Eligibility: 18 Years and older
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 17
States / cities: Rolling Hills, California • San Diego, California • Torrance, California + 13 more

Conditions: Urinary Incontinence
Interventions: patient acceptable symptom state (PASS); Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Depression
Interventions: Fluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram; Drug · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 18 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more

Conditions: Major Depressive Disorder
Interventions: ketamine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Aging, Depression, Cognitive Symptom
Interventions: Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation); Behavioral · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Depression, Substance Abuse, Substance Use, Neuroimaging, Dual Diagnosis
Interventions: Creatine monohydrate; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 13 Years to 64 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Inflammatory Bowel Disease, Depression
Interventions: Cognitive Behavioral Therapy, Supportive Non-directive Therapy (SNDT); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 9 Years to 17 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Cognitive Deficit
Interventions: Brain Stimulation; Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pain, Chronic, Pain, Musculoskeletal, Anxiety
Interventions: dCBT; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception, Postpartum Depression, Lactation
Interventions: Depot medroxyprogesterone acetate; Drug
Lead sponsor: Beatrice Chen; Other
Eligibility: 18 Years and older · Female only
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: rTMS therapy; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder, Bipolar Disorder
Interventions: Mindfulness-based cognitive therapy; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Los Angeles, California • Boulder, Colorado

Search by objective public record fields.

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder

Trial of a Nationwide Cognitive-Affective Remediation Training Intervention in Depression

A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)

A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

Telehealth-Based Exercise Program to Treat Fatigue in MS

The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

Maintenance TMS in Treatment Resistant Depression

The Effect of EFT on Psychological States in a Veterans Population

Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients

Fear of Recurrence and Stopping Immunotherapy

Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety

Patient Satisfaction Survey of Non-surgical Urinary Incontinence Treatment

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

Cognitive Enhancement in Depression (The COG-D Study)

Creatine as a Treatment Option for Depression in Methamphetamine Using Females

Reducing Depressive Symptoms in Physically Ill Youth

Studying the Effects of Brain Stimulation on Cognitive Control and Associated EEG in Human Subjects.

Assessment of the Efficacy of Digital CBT for Anxiety in Adults With Chronic Musculoskeletal Pain

Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression

Biomarkers of Depression and Treatment Response

Mindfulness-Based Cognitive Therapy for Perinatal Women With Mood Disorders